These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 32493321)

  • 1. Variability in blood lipids affects the neutrophil to lymphocyte ratio in patients undergoing elective percutaneous coronary intervention: a retrospective study.
    Zhao L; Xu T; Li Y; Luan Y; Lv Q; Fu G; Zhang W
    Lipids Health Dis; 2020 Jun; 19(1):124. PubMed ID: 32493321
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Correlation between neutrophil/lymphocyte ratio combined with low-density lipoprotein cholesterol/high-density lipoprotein cholesterol ratio and severity of coronary artery disease in patients with acute coronary syndrome].
    Yuan S; Pu T; Wang Z; Li L; Gao P; Zhang L; Ma Y; Qi Q; Fan X
    Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2022 Mar; 34(3):274-279. PubMed ID: 35574745
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of the low-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio and major adverse cardiac and cerebrovascular events in patients with coronary heart disease undergoing percutaneous coronary intervention: a cohort study.
    Ren X; Wang X
    Curr Med Res Opin; 2023 Sep; 39(9):1175-1181. PubMed ID: 37560911
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The relationship between NLR, LDL-C/HDL-C, NHR and coronary artery disease.
    Yuan S; Li L; Pu T; Fan X; Wang Z; Xie P; Li P
    PLoS One; 2024; 19(7):e0290805. PubMed ID: 38985788
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Atherogenic Lipoprotein Subfractions Determined by Ion Mobility and First Cardiovascular Events After Random Allocation to High-Intensity Statin or Placebo: The Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) Trial.
    Mora S; Caulfield MP; Wohlgemuth J; Chen Z; Superko HR; Rowland CM; Glynn RJ; Ridker PM; Krauss RM
    Circulation; 2015 Dec; 132(23):2220-9. PubMed ID: 26408274
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effects of atorvastatin on interventional therapy in patients with acute myocardial infarction.
    Wang K; Chen L; Liu L; Cui Y; Zhang X; Jiang J
    Minerva Med; 2019 Apr; 110(2):101-106. PubMed ID: 29696937
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Visit-to-visit variability of lipid measurements as predictors of cardiovascular events.
    Waters DD; Bangalore S; Fayyad R; DeMicco DA; Laskey R; Melamed S; Barter PJ
    J Clin Lipidol; 2018; 12(2):356-366. PubMed ID: 29310989
    [TBL] [Abstract][Full Text] [Related]  

  • 8. LDL-C/HDL-C ratio in subjects with cardiovascular disease and a low HDL-C: results of the RADAR (Rosuvastatin and Atorvastatin in different Dosages And Reverse cholesterol transport) study.
    Jukema JW; Liem AH; Dunselman PH; van der Sloot JA; Lok DJ; Zwinderman AH
    Curr Med Res Opin; 2005 Nov; 21(11):1865-74. PubMed ID: 16307708
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HDL-C: role as a risk modifier.
    Barter P
    Atheroscler Suppl; 2011 Nov; 12(3):267-70. PubMed ID: 22152280
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association between the variability of non-high-density lipoprotein cholesterol and the neutrophil-to-lymphocyte ratio in patients with coronary heart disease.
    Chen Y; Zhang S; Tao Y; Hu W; Li D; Shen X; Li Y; Lin M; Zhang W; Liu X; Xie D
    Front Cardiovasc Med; 2023; 10():1254125. PubMed ID: 38075976
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
    Cziraky MJ; Watson KE; Talbert RL
    J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pitavastatin: novel effects on lipid parameters.
    Chapman MJ
    Atheroscler Suppl; 2011 Nov; 12(3):277-84. PubMed ID: 22152282
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Importance of the lipid-related pathways in the association between statins, mortality, and cardiovascular disease risk: The Multi-Ethnic Study of Atherosclerosis.
    Talbot D; Delaney JAC; Sandfort V; Herrington DM; McClelland RL
    Pharmacoepidemiol Drug Saf; 2018 Apr; 27(4):365-372. PubMed ID: 29405501
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis.
    Nicholls SJ; Tuzcu EM; Sipahi I; Grasso AW; Schoenhagen P; Hu T; Wolski K; Crowe T; Desai MY; Hazen SL; Kapadia SR; Nissen SE
    JAMA; 2007 Feb; 297(5):499-508. PubMed ID: 17284700
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lowering Targeted Atherogenic Lipoprotein Cholesterol Goals for Patients at "Extreme" ASCVD Risk.
    Rosenblit PD
    Curr Diab Rep; 2019 Nov; 19(12):146. PubMed ID: 31754844
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Jeremiah Metzger Lecture: cholesterol, inflammation and atherosclerotic cardiovascular disease: is it all LDL?
    Gotto AM
    Trans Am Clin Climatol Assoc; 2011; 122():256-89. PubMed ID: 21686232
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of atorvastatin on lipid profile and non-traditional cardiovascular risk factors in diabetic patients on hemodialysis.
    Navarro JF; Mora C; Muros M; García-Idoate G
    Nephron Clin Pract; 2003; 95(4):c128-35. PubMed ID: 14694274
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evidence for changing lipid management strategy to focus on non-high density lipoprotein cholesterol.
    Su X; Kong Y; Peng D
    Lipids Health Dis; 2019 Jun; 18(1):134. PubMed ID: 31170997
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Are all statins the same? Focus on the efficacy and tolerability of pitavastatin.
    da Silva PM
    Am J Cardiovasc Drugs; 2011; 11(2):93-107. PubMed ID: 21446776
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Triglyceride-Rich Lipoprotein Cholesterol and Risk of Cardiovascular Events Among Patients Receiving Statin Therapy in the TNT Trial.
    Vallejo-Vaz AJ; Fayyad R; Boekholdt SM; Hovingh GK; Kastelein JJ; Melamed S; Barter P; Waters DD; Ray KK
    Circulation; 2018 Aug; 138(8):770-781. PubMed ID: 29618599
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.